As anti-sclerostin drugs such as romosozumab [60] and raloxifene [61] are already approved for the treatment of overt postmenopausal osteoporosis, the impact of these drugs on sclerostin–bone metabolism interactions in OSCC should also be evaluated to assess a potential therapeutic benefit for the treatment of patients with advanced tumor stage. The gene discussed is SOST; the disease is postmenopausal osteoporosis.